MedTrace Logo

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

NCT06218199 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-01-29

No results posted yet for this study

Summary

The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Furosemide

oral administration

DRUG

Torsemide

oral administration

DRUG

Bumetanide

oral administration

DRUG

sacubitril/valsartan

oral administration

DRUG

Hydralazine

oral administration

DRUG

Isosorbide Dinitrate

oral administration

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Heart Center Research, LLC

    lead NETWORK

Principal Investigators

  • Jay Dinerman, MD · Heart Center Research, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06218199 on ClinicalTrials.gov